Woodline Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Woodline Partners’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-220,676	Closed	-$16.6M	–	958
2022 Q2	$16.6M	Buy	220,676 +137,820	+166%	+$6.12M	0.26%	121
2022 Q1	$2.23M	Sell	82,856 -17,788	-18%	-$598K	0.04%	368
2021 Q4	$4.8M	Buy	100,644 +50,416	+100%	+$2.25M	0.07%	287
2021 Q3	$3.34M	Buy	50,228 +3,228	+7%	+$230K	0.05%	321
2021 Q2	$3.67M	Buy	47,000 +800	+2%	+$59.1K	0.07%	266
2021 Q1	$4.37M	Buy	+46,200	New	+$5.49M	0.1%	207
2020 Q1	–	Sell	-199,378	Closed	-$12.4M	–	181
2019 Q4	$12.4M	Buy	+199,378	New	+$9.49M	0.51%	61

Woodline Partners's TPTX Position: Q3 2022 in Review

Woodline Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 220,676 shares — an estimated $16.6M sold.

Woodline Partners first reported a position in TPTX in Q4 2019 and held it in 7 quarters. The position peaked at $16.6M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Woodline Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Woodline Partners sold 220,676 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $16.6M.
Woodline Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Woodline Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $16.6M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.